Smital Shah's guest appearances

Smital Shah

CFO THOUGHT LEADER

Business Of Biotech

Anixa Biosciences

Amolyt Pharma

Ivor Macleod

Rajesh Gupta

Dave Jones

Jeff Epstein

John Collins

Eric Johnson

Michael Tannenbaum

Kraft Heinz

Chris Baker

Bob Feller

Dave Kellogg

Jeff Nichols

James Taylor

OwlTail

Smital Shah brings a trifecta of chemical engineering, consulting, and finance experience earned at heavyweight companies like JP Morgan, Leerink, and Gilead to her role at clinical-stage RNA therapy biotech ProQR Therapeutics. We sat down for a deep conversation on the recipe for successful business and finance operations in an emerging biopharma organization.Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Smital Shah brings a trifecta of chemical engineering, consulting, and finance experience earned at heavyweight companies like J<a href="https://www.jpmorgan.com/" rel="nofollow" target="_blank">P Morgan</a>, <a href="https://www.svbleerink.com/" rel="nofollow" target="_blank">Leerink</a>, and <a href="https://www.gilead.com/" rel="nofollow" target="_blank">Gilead</a> to her role at clinical-stage RNA therapy biotech <a href="https://www.proqr.com/" rel="nofollow" target="_blank">ProQR Therapeutics</a>. We sat down for a deep conversation on the recipe for successful business and finance operations in an emerging biopharma organization.Subscribe to the NEW #BusinessofBiotech newsletter at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a> for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a>!

Foundations Of Biopharma Finance With Smital Shah

As an Indian citizen living in the United States and working for a Dutch company, CFO Smital Shah frequently spends her days on conference calls with investors from Asia, Israel, or Europe. On every investor call, at every board meeting, and at every employee gathering, the same question gets asked: “How far is ProQR from serving patients?” Each time she hears this, the firm’s worldly finance leader provides a thoughtful and measured response. This is a question that punctuates the tenure of finance chiefs inside every clinical stage start-up, and one that Shah says has led her to seek out any synergies that she can between the finance function’s accounting and compliance processes and ProQR’s greater goal of creating medicines for patients who suffer from rare diseases. Shah asks: “How do we facilitate—within the confines of finance—what we need to do in order to achieve this?” ProQR expects to have collected the necessary data from its ongoing clinical trials to seek out approval for its new medicine from the Food and Drug Administration by early 2021 or perhaps sooner. As for the “confines of finance,” any functional borders within ProQR have clearly already been breached by Shah, who implores her finance team to regularly listen to those beyond the functional boundaries. “This is about understanding that you as an individual contributor cannot always affect the magnitude of change that you want. Change will depend on your team and all of the stakeholders around it. So I think that this is about stakeholder management and truly listening to all and realizing that you achieve impact as a group,” explains Shah, whose finance leadership mind-set is perhaps the offspring of a borderless career. –Jack Sweeney Subscribe to CFO Thought Leader Quarterly magazine or buy our latest issue HERE

As an Indian citizen living in the United States and working for a Dutch company, CFO Smital Shah frequently spends her days on conference calls with investors from Asia, Israel, or Europe. On every investor call, at every board meeting, and at every employee gathering, the same question gets asked: “How far is ProQR from serving patients?” Each time she hears this, the firm’s worldly finance leader provides a thoughtful and measured response. This is a question that punctuates the tenure of finance chiefs inside every clinical stage start-up, and one that Shah says has led her to seek out any synergies that she can between the finance function’s accounting and compliance processes and ProQR’s greater goal of creating medicines for patients who suffer from rare diseases. Shah asks: “How do we facilitate—within the confines of finance—what we need to do in order to achieve this?” ProQR expects to have collected the necessary data from its ongoing clinical trials to seek out approval for its new medicine from the Food and Drug Administration by early 2021 or perhaps sooner. As for the “confines of finance,” any functional borders within ProQR have clearly already been breached by Shah, who implores her finance team to regularly listen to those beyond the functional boundaries. “This is about understanding that you as an individual contributor cannot always affect the magnitude of change that you want. Change will depend on your team and all of the stakeholders around it. So I think that this is about stakeholder management and truly listening to all and realizing that you achieve impact as a group,” explains Shah, whose finance leadership mind-set is perhaps the offspring of a borderless career. –Jack Sweeney Subscribe to CFO Thought Leader Quarterly magazine or buy our latest issue <a href="https://cfothoughtleaderquarterly.com" rel="nofollow" target="_blank">HERE</a>

541: Energizing Your Stakeholder Network  | Smital Shah, CFO, ProQR